Anika Therapeutics(CH:AKP)
CH:AKP
Anika Therapeutics financials statements
Anika Therapeutics (AKP) Ratios
0 Followers
Anika Therapeutics Ratios
CH:AKP's free cash flow for Q3 2026 was $6.72M. For the 2026 fiscal year, CH:AKP's free cash flow was decreased by $-1.66M and operating cash flow was $8.38M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 4.72 | 4.88 | 5.26 | 6.07 | 5.66 |
| Quick Ratio | 3.86 | 3.85 | 4.47 | 4.65 | 4.45 |
| Cash Ratio | 2.62 | 2.39 | 2.21 | 3.09 | 3.17 |
| Solvency Ratio | -0.11 | -0.99 | -1.17 | -0.01 | 0.31 |
| Operating Cash Flow Ratio | 0.51 | 0.23 | -0.06 | 0.16 | 0.28 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 56.55M | $ 64.90M | $ 104.94M | $ 105.98M | $ 108.08M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.14 | 0.13 | 0.10 | 0.09 | 0.06 |
| Debt-to-Equity Ratio | 0.18 | 0.17 | 0.13 | 0.11 | 0.07 |
| Debt-to-Capital Ratio | 0.15 | 0.14 | 0.12 | 0.10 | 0.07 |
| Long-Term Debt-to-Capital Ratio | 0.14 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.33 | 1.32 | 1.27 | 1.22 | 1.21 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.18 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 1.83 | 1.76 | 1.89 | 2.12 | 1.46 |
| Net Debt to EBITDA | 8.73 | -5.54 | -2.72 | -3.05 | 17.64 |
| Profitability Margins | |||||
| Gross Profit Margin | 56.56% | 63.38% | 68.33% | 64.33% | 56.12% |
| EBIT Margin | -8.25% | -2.31% | 0.70% | 3.22% | -12.50% |
| EBITDA Margin | -3.17% | 4.47% | 12.47% | 15.95% | -2.82% |
| Operating Profit Margin | -9.80% | -4.25% | 0.70% | 3.22% | 1.77% |
| Pretax Profit Margin | -8.25% | -2.31% | 2.61% | 3.80% | 1.64% |
| Net Profit Margin | -9.64% | -47.02% | -68.44% | -13.05% | 2.80% |
| Continuous Operations Profit Margin | -8.85% | -7.36% | -2.85% | 1.93% | 2.80% |
| Net Income Per EBT | 116.90% | 2039.98% | -2619.36% | -343.64% | 170.33% |
| EBT Per EBIT | 84.22% | 54.19% | 373.93% | 117.82% | 92.81% |
| Return on Assets (ROA) | -5.72% | -27.81% | -30.55% | -4.26% | 1.19% |
| Return on Equity (ROE) | -7.58% | -36.62% | -38.95% | -5.20% | 1.44% |
| Return on Capital Employed (ROCE) | -6.56% | -2.84% | 0.35% | 1.14% | 0.82% |
| Return on Invested Capital (ROIC) | -6.48% | -2.81% | -0.38% | 0.58% | 0.82% |
| Return on Tangible Assets | -6.03% | -29.20% | -31.74% | -5.56% | 1.61% |
| Earnings Yield | -7.90% | -23.27% | -24.89% | -3.45% | 0.80% |
| Efficiency Ratios | |||||
| Receivables Turnover | 4.76 | 5.08 | 4.58 | 3.29 | 4.95 |
| Payables Turnover | 8.11 | 7.82 | 6.18 | 4.48 | 8.50 |
| Inventory Turnover | 2.61 | 1.84 | 1.57 | 1.02 | 1.80 |
| Fixed Asset Turnover | 1.70 | 1.85 | 1.86 | 1.44 | 2.16 |
| Asset Turnover | 0.59 | 0.59 | 0.45 | 0.33 | 0.43 |
| Working Capital Turnover Ratio | 1.31 | 1.08 | 0.88 | 0.81 | 1.06 |
| Cash Conversion Cycle | 171.57 | 223.04 | 253.60 | 386.90 | 233.42 |
| Days of Sales Outstanding | 76.64 | 71.82 | 79.65 | 111.04 | 73.70 |
| Days of Inventory Outstanding | 139.91 | 197.92 | 233.04 | 357.43 | 202.67 |
| Days of Payables Outstanding | 44.99 | 46.69 | 59.09 | 81.56 | 42.96 |
| Operating Cycle | 216.55 | 269.74 | 312.70 | 468.47 | 276.38 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.78 | 0.37 | -0.12 | 0.30 | 0.58 |
| Free Cash Flow Per Share | 0.30 | -0.16 | -0.49 | -0.21 | 0.23 |
| Dividend Paid and CapEx Coverage Ratio | 1.64 | 0.70 | -0.33 | 0.59 | 1.63 |
| Capital Expenditure Coverage Ratio | 1.64 | 0.70 | -0.33 | 0.59 | 1.63 |
| Operating Cash Flow Coverage Ratio | 0.43 | 0.21 | -0.06 | 0.14 | 0.40 |
| Operating Cash Flow to Sales Ratio | 0.10 | 0.05 | -0.01 | 0.04 | 0.06 |
| Free Cash Flow Yield | 3.17% | -0.96% | -2.17% | -0.71% | 0.63% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -12.64 | -4.30 | -4.02 | -29.01 | 124.82 |
| Price-to-Sales (P/S) Ratio | 1.22 | 2.02 | 2.75 | 3.79 | 3.49 |
| Price-to-Book (P/B) Ratio | 0.96 | 1.57 | 1.56 | 1.51 | 1.80 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 31.59 | -103.95 | -46.03 | -140.07 | 158.57 |
| Price-to-Operating Cash Flow Ratio | 12.32 | 44.85 | -185.74 | 97.76 | 61.45 |
| Price-to-Earnings Growth (PEG) Ratio | 0.16 | 0.13 | -0.01 | 0.06 | -1.07 |
| Enterprise Value Multiple | -29.78 | 39.69 | 19.33 | 20.68 | -106.31 |
| Enterprise Value | 106.56M | 212.61M | 291.11M | 375.57M | 442.56M |
| EV to EBITDA | -29.78 | 39.69 | 19.33 | 20.68 | -106.31 |
| EV to Sales | 0.94 | 1.77 | 2.41 | 3.30 | 2.99 |
| EV to Free Cash Flow | 24.43 | -91.21 | -40.35 | -122.06 | 136.00 |
| EV to Operating Cash Flow | 9.52 | 39.35 | -162.81 | 85.18 | 52.70 |
| Tangible Book Value Per Share | 9.33 | 9.81 | 13.79 | 13.98 | 13.67 |
| Shareholders’ Equity Per Share | 10.01 | 10.46 | 14.48 | 19.61 | 19.94 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.07 | -2.19 | 2.09 | 0.49 | -0.70 |
| Revenue Per Share | 7.87 | 8.15 | 8.24 | 7.82 | 10.26 |
| Net Income Per Share | -0.76 | -3.83 | -5.64 | -1.02 | 0.29 |
| Tax Burden | 1.17 | 20.40 | -26.19 | -3.44 | 1.70 |
| Interest Burden | 1.00 | 1.00 | 3.74 | 1.18 | -0.13 |
| Research & Development to Revenue | 0.23 | 0.21 | 0.18 | 0.16 | 0.18 |
| SG&A to Revenue | 0.44 | 0.46 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.09 | 0.11 | 0.13 | 0.13 | 0.08 |
| Income Quality | -1.03 | -0.10 | 0.02 | -0.30 | 2.03 |
Currency in USD
